Federal regulations and reimbursement for PET

Area of Science:

• Nuclear Medicine
• Radiopharmaceuticals
• Medical Imaging

Background:

• The regulatory landscape for Positron Emission Tomography (PET) drugs has evolved, with updated FDA findings on safety and efficacy.
• Medicare's national coverage policy for PET has expanded, including new indications and restrictions effective July 2001.
• The Hospital Outpatient Prospective Payment System (HOPPS) has established new payment rates for PET procedures.

Purpose of the Study:

• To review recent regulatory and reimbursement changes impacting PET.
• To discuss the implications of these changes for PET center development and operation.
• To equip nuclear medicine technologists with knowledge of FDA regulations, Medicare coverage, and billing codes for PET.

Main Methods:

• Review of FDA drug approval findings and production guidelines.
• Analysis of national Medicare coverage policies and payment systems (HOPPS).
• Identification of approved PET indications and associated billing codes.

Main Results:

• FDA has published safety and efficacy findings for key PET drugs and guidelines for production.
• Medicare coverage for PET has been expanded, with specific indications and restrictions.
• New payment rates under HOPPS are established for PET procedures.

Conclusions:

• Regulatory clarity and expanded reimbursement are facilitating rapid clinical adoption of PET.
• Staying informed about these evolving changes is essential for the successful growth of nuclear medicine programs offering PET services.